期刊文献+

以案例分析谈临床药师在神经外科的临床药学实践 被引量:2

Introduction of clinical pharmaceutical practice of pharmacists in neurosurgery department:a case analysis
原文传递
导出
摘要 目的:探讨临床药师在神经外科开展精准药学监护的切入点。方法:临床药师通过参与术后颅内感染的抗感染治疗方案的制定、以基因导向和群体药动学为基础设计苯妥英钠剂量个体化给药方案、分析医嘱找出药物间潜在的不良相互作用等角度开展工作。结果:术后颅内感染的患者,通过临床药师提供精准治疗方案,患者感染常很快得到有效控制;苯妥英钠剂量个体化给药可使其在术后7 d内达到有效治疗浓度;通过分析医嘱避免了苯妥英钠与质子泵抑制剂兰索拉唑、奥美拉唑之间可能存在的不良相互作用。结论:上述3个切入点体现了临床药师开展精准药学监护的内涵,在神经外科治疗团队中发挥了重要作用。 Objective: To introduce the breakthrough point for precise pharmaceutical care of pharmacists in neurosurgery department. Methods: Clinical pharmacists participated in the forming of precise anti-infective regimen, designed the individualized drug administration of phenytoin on the basis of population pharmacokinetics, and found the potential adverse interaction by analysizing the dictor's advice. Results: Infection was timely controlled by precise treatment regimen provided by clinical physicians and clinical pharmacists. Phenytoin blood drug concentrations can reach the therapeutic range within 7 days after the operation by individualized dose design, and adverse interactions between phenytoin and proton pump inhibitors, such as lansoprazole and omeprazole, were reduced by analyzing the doctor's advice. Conclusion: The three breakthrough points may present the internal implication of precise pharmaceutical care carried by clinical pharmacists, which play an important role in neurosurgery treatment teams.
出处 《中国新药杂志》 CAS CSCD 北大核心 2017年第11期1339-1344,共6页 Chinese Journal of New Drugs
关键词 临床药师 临床药学 实践 神经外科 clinical pharmacists clinical pharmacy practice neurosurgery department
  • 相关文献

参考文献6

二级参考文献61

  • 1王强,张峥,唐明忠,石广志,赵立红,郑一,周建新.神经外科加强医疗病房的细菌耐药性监测[J].中华医院感染学杂志,2004,14(6):680-683. 被引量:28
  • 2余英教,黄细富,侯树勇,伍志德,白奕斌,黄永华.神经外科住院患者医院感染分析[J].中华医院感染学杂志,2004,14(9):996-998. 被引量:18
  • 3杨平 谭方伦.鞘内注射庆大霉素致脊髓功能严重障碍3例[J].中国神经精神疾病杂志,1999,25(4):229-229. 被引量:7
  • 4Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of digoxin in Japanese neonates. J Clin Pharm Ther 2007; 32: 381-6. 被引量:1
  • 5Martin-Suarez A, Falcao AC, Outeda M, Hernandez FJ, Gonzalez MC, Quero M, et al. Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit 2002; 24: 742-5. 被引量:1
  • 6Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol 2001; 57: 19-24. 被引量:1
  • 7Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population pharmacokinetics of digoxin in Japanese patients. Clin Pharmacokinet 2001; 40: 773-81. 被引量:1
  • 8Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. J Clin Pharmaco12003; 55: 544-51. 被引量:1
  • 9Hornestam B, Jerling M, Karlsson MO, Held P. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol 2003; 58: 747-55. 被引量:1
  • 10EL Desoky ES, Nagaraja NV, Derendorf H. Population pharmacokinetics of digoxin in Egyptian pediatric patients: Impact of one data point utilization. Am J Ther 2002; 9: 492-8. 被引量:1

共引文献162

同被引文献10

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部